A new CAR-T cell therapy has shown promising early results against glioblastoma, a highly aggressive brain cancer. In a phase 1 trial, all three patients experienced rapid tumour shrinkage, including near-complete regression in one case. Though temporary, these results mark a breakthrough, offering hope for improved, personalised treatments and better outcomes in hard-to-treat brain tumours.